Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Antivirals could be a vital weapon in the COVID-19 pandemic endgame

By Brian Buntz | October 6, 2021

SARS-CoV-2 COVID-19 antivirals

Transmission electron microscope image of SARS-CoV-2. Image from NIH.

Antivirals have several advantages over vaccines. They tend to be broadly effective against viral variants and offer faster-acting protection than vaccines. In addition, antivirals are usually simple to transport and don’t require ultra-cold storage. And oral antivirals would have an advantage in terms of the speed of protection they offer. For SARS-CoV-2, antivirals also could provide an alternative to vaccines in the scores of vaccine-hesitant people. Additionally, antivirals have a proven track record against other viruses like HIV and hepatitis C, where vaccines aren’t available.

“We need antivirals,” surmised Kamlendra Singh, a molecular microbiology and immunology professor at the University of Missouri (Columbia, Missouri).

“It’s not that the vaccines aren’t working. They are working wonders,” Singh said. But antivirals will likely emerge as an indispensable tool as SARS-CoV-2 continues to mutate, Singh said.

Antivirals can limit the multiplication of virus in the body, leading to milder illness. They also could potentially inhibit transmission.

Kamlendra Singh

Kamlendra Singh

Already, the Delta variant has served to stress-test the currently available vaccines, which remain effective but less so than against earlier variants. The Delta variant is presently responsible for 99% of COVID-19 infections, according to the CDC. It has also caused significant surges in disease in India, Israel, the U.K. and U.S.

“I don’t think Delta will be the last [wave], Singh said.

The spread of HIV in past decades may provide some indication of what to anticipate from SARS-CoV-2. “People learn from experience,” Singh said. And researchers have substantial experience studying HIV.

Although HIV is a lentivirus (a genus of retrovirus) and SARS-CoV-2 is a coronavirus, both viruses encode their genome in RNA and mutate relatively quickly. While HIV mutates faster than SARS-CoV-2, the novel coronavirus mutates at least 50% faster than researchers anticipated, according to researchers at the University of Bath.

There are now hundreds of variants of HIV, which are known as circulating recombinant forms. “If HIV can mutate that much and still have structural integrity, I don’t see why coronavirus could not do that,” Singh said.

And yet, antiretroviral therapy has transformed the treatment landscape for HIV, leading to substantial improvements in morbidity and mortality.

But while a number of scientists and companies are working on antivirals for SARS-CoV-2, it may be too early to tell which will find broad use.

Merck and Ridgeback Biotherapeutics, Pfizer, Roche and Atea, Pardes Biosciences and university scientists are all developing antivirals for the pandemic.

An interim analysis from 775 patients enrolled in the Phase 3 MOVe-OUT study of Merck’s and Ridgeback’s molnupiravir found the drug cut the risk of hospitalization or death by approximately 50%.

While data to date have been promising, “we need more data involving thousands of patients” to evaluate the potential of a given antiviral, Singh said. “But I definitely think that the discovery of antivirals is very important,” he concluded.


Filed Under: Infectious Disease
Tagged With: antivirals, coronavirus, HIV, pandemic, SARS-CoV-2
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Secretary of Health removes all current members of the CDC advisory committee on immunization practices
covid-19 vaccine
FDA COVID booster pullback jolts vaccine stocks before gains cool
Coronavirus Covid-19 background - 3d rendering
Pregnancy associated with less long COVID: Researchers call for studies on protective biology
How technology advances are helping scientists unlock the mysteries of zoonotic diseases
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE